Tag: Psilera Bioscience - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Post published:December 7, 2021
Post category:Press Release

Read more about the article Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction

Post published:August 26, 2021
Post category:Press Release

Read more about the article Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

Post published:August 12, 2021
Post category:Press Release

Read more about the article Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Post published:July 1, 2021
Post category:Press Release

Read more about the article Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

Post published:February 25, 2021
Post category:Press Release

Read more about the article Jackie von Salm, Co-founder and CSO at Psilera Bioscience

Jackie von Salm, Co-founder and CSO at Psilera Bioscience

Post published:December 17, 2020
Post category:Interview

Read more about the article Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library

Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library

Post published:December 16, 2020
Post category:Press Release

Read more about the article Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies

Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies

Post published:July 1, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.